Vogl, NY

 

Avatar

POOF: And the Benefit Disappeared! What We Learn From PenelopeB. A Negative Adjuvant CDK4/6 Inhibitor Trial for Resected HR Positive Breast Cancer

By Steven Vogl 18 Videos
1,493 views
December 23, 2020
Comments 2
Login to view comments. Click here to Login

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh
Breast
54:19

Adjuvant Abemaciclib - Are The Data Sufficient? Maybe

Steven Vogl

265 views
48:18

SABCS 2021 Update: SOFT and TEXT are Important - Ovarian Function Su…

Steven Vogl

762 views
25:09

SABCS 2021 on Using the Appearance of a Resistance Mutation in Perip…

SABCS 2021 Conference Coverage on VuMedi

S. Vogl

479 views
32:47

SABCS 2021 Updated Results From the RxPONDER Trial in HR+/HER2- Brea…

SABCS 2021 Conference Coverage on VuMedi

S. Vogl

1.4K views
27:32

We Need Overall Survival Results From Keynote 355 Now!

Steven Vogl

819 views
47:44

Ovarian Suppression or Cytotoxic Chemotherapy: What Is the Mechanism…

Steven Vogl

1.2K views
29:48

SABCS 2020 RxPONDER Updates on HR+ Node-Positive EBC: Are Postmenopa…

Steven Vogl

2.1K views
18:37

POOF: And the Benefit Disappeared! What We Learn From PenelopeB. A N…

Steven Vogl

1.5K views
25:41

Do PD-1 Drugs Really Help Patients With mTNBC to Live Longer and Bet…

Steven Vogl

1.5K views
30:31

Discussion on 2020 ESMO Update on CDK4/6i in Adjuvant ER+ Resected B…

Steven Vogl

1.3K views